SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT") announces today that Dr. Alan Moore, President and CEO, will be presenting at the EDC's 8th Annual Life Science Conference in Miami, Florida. Dr. Moore was invited to discuss SCT's unique regenerative stem cell therapy and how it will be the frontier of personalized healthcare specifically in the key areas of stroke, traumatic brain injury and multiple sclerosis.

The University of Miami will host EDCs 8th Annual Life Science Conference, Biotech 2009, at the Hyatt Regency in downtown Miami. The conference brings regional industry and academia together for one day to preview translational research being done in South Florida, and to explore promising new areas of research and collaboration.

About EDC's 8th Annual Life Science Conference, BioTech 2009 (http://www.edc-tech.org/clientuploads/BioAgenda09.pdf ): South Florida is a vast region characterized by unique educational institutions and organizations, both large and small, involved in all aspects of the Life Sciences from research, development and commercialization of novel diagnostic and therapeutic products to world renowned treatment centers that offer the latest advancements in patient care. This year's conference will explore the burgeoning and sometimes controversial field of regenerative medicine, harnessing the body's own power to regenerate. Discussion topics include Stem cell-based treatments for heart disease, diabetes and dental problems; Biomaterials for replacement body parts; the intersection of regenerative medicine and personalized healthcare; and how to handle IP, regulatory, licensing and ethics issues.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological function lost due to disease or injury. SCT's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President and CEO (403) 245-5495 ext.224 Email: amoore@stemcellthera.com Stem Cell Therapeutics Corp. Chloe Douglas-Crampton Investor Relations (403) 245-5495 ext. 221 Email: crampton@stemcellthera.com Website: www.stemcellthera.com